GlassScriptPhysician profile
Faraz M Khan
NPI 1770559957
$16,802.75
in general payments reported to CMS, 2019-2025
29 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $488 · 2021: $346 · 2022: $588 · 2023: $451 · 2024: $1,111 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139 · Education: $35.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,139.28 |
| Education | $35.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $11,918.33 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $718.04 | 2019-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $536.72 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $421.28 | 2022-2025 | |
| Horizon Therapeutics Plc | $397.89 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $368.13 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $345.21 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $330.98 | 2019-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $198.01 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $170.64 | 2022-2025 | Filspari |
| Novo Nordisk INC | $167.17 | 2024-2025 | Ozempic, Rybelsus, Rivfloza |
| Ardelyx, INC. | $157.46 | 2024-2025 | Ibsrela |
| Baxter Healthcare | $118.48 | 2020 | |
| Outset Medical INC | $113.64 | 2020 | |
| Amgen INC. | $103.44 | 2024-2025 | Krystexxa, Tavneos |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.63 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $87.76 | 2023-2025 | |
| Boston Scientific Corporation | $84.63 | 2020 | |
| Fresenius USA Marketing, INC. | $83.90 | 2019-2025 | Velphoro, Velphoro |
| Ani Pharmaceuticals, INC. | $76.75 | 2025 | Purified Cortrophin Gel |
| Biosense Webster, INC. | $67.90 | 2024 | Carto 3 |
| Amarin Pharma, INC. | $44.79 | 2019-2020 | |
| Recor Medical INC | $36.65 | 2025 | Paradise Ultrasound Renal Denervation System |
| Medtronic, INC. | $35.65 | 2023 | Ellipsys Vascular Access System |
| Lilly USA, LLC | $35.53 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $23.94 | 2023 | Benlysta |
| Alnylam Pharmaceuticals INC. | $22.33 | 2023 | Oxlumo |
| Scpharmaceuticals INC. | $19.25 | 2025 | |
| Aurinia Pharma U.S., INC. | $15.62 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faraz Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.